S100A9, a pro-inflammatory
alarmin, is up-regulated in inflamed tissues. However, the role of S100A9 in regulating neutrophil activation,
inflammation and lung damage in
sepsis is not known. Herein, we hypothesized that blocking S100A9 function may attenuate neutrophil recruitment in septic
lung injury. Male C57BL/6 mice were pretreated with the S100A9 inhibitor
ABR-238901 (10 mg/kg), prior to cercal
ligation and
puncture (CLP). Bronchoalveolar lavage fluid (BALF) and lung tissue were harvested for analysis of neutrophil infiltration as well as
edema and
CXC chemokine production. Blood was collected for analysis of membrane-activated complex-1 (Mac-1) expression on neutrophils as well as
CXC chemokines and
IL-6 in plasma. Induction of CLP markedly increased plasma levels of S100A9.
ABR-238901 decreased CLP-induced neutrophil infiltration and
edema formation in the lung. In addition, inhibition of S100A9 decreased the CLP-induced up-regulation of Mac-1 on neutrophils. Administration of
ABR-238901 also inhibited the CLP-induced increase of CXCL-1, CXCL-2 and
IL-6 in plasma and lungs. Our results suggest that S100A9 promotes neutrophil activation and pulmonary accumulation in
sepsis. Targeting S100A9 function decreased formation of
CXC chemokines in circulation and lungs and attenuated
sepsis-induced lung damage. These novel findings suggest that S100A9 plays an important pro-inflammatory role in
sepsis and could be a useful target to protect against the excessive
inflammation and lung damage associated with the disease.